Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group

Blood (2022) 140 (Supplement 1): 9347–9349.

https://doi.org/10.1182/blood-2022-160073

Published: 2022

Journal Articles

Genetic and phenotypic attributes of splenic marginal zone lymphoma

Ferdinando Bonfiglio, Alessio Bruscaggin, Francesca Guidetti, Lodovico Terzi di Bergamo, Martin Faderl, Valeria Spina, Adalgisa Condoluci, Luisella Bonomini, Gabriela Forestieri, Ricardo Koch, Deborah Piffaretti, Katia Pini, Maria Cristina Pirosa, Micol Giulia Cittone, Alberto Arribas, Marco Lucioni, Guido Ghilardi, Wei Wu, Luca Arcaini, Maria Joao Baptista, Gabriela Bastidas, Silvia Bea, Renzo Boldorini, Alessandro Broccoli, Marco Matteo Buehler, Vincenzo Canzonieri, Luciano Cascione, Luca Ceriani, Sergio Cogliatti, Paolo Corradini, Enrico Derenzini, Liliana Devizzi, Sascha Dietrich, Angela Rita Elia, Fabio Facchetti, Gianluca Gaidano, Juan Fernando Garcia, Bernhard Gerber, Paolo Ghia, Maria Gomes da Silva, Giuseppe Gritti, Anna Guidetti, Felicitas Hitz, Giorgio Inghirami, Marco Ladetto, Armando Lopez-Guillermo, Elisa Lucchini, Antonino Maiorana, Roberto Marasca, Estella Matutes, Veronique Meignin, Michele Merli, Alden Moccia, Manuela Mollejo, Carlos Montalban, Urban Novak, David Graham Oscier, Francesco Passamonti, Francesco Piazza, Stefano Pizzolitto, Alessandro Rambaldi, Elena Sabattini, Gilles Salles, Elisa Santambrogio, Lydia Scarfò, Anastasios Stathis, Georg Stüssi, Julia T. Geyer, Gustavo Tapia, Corrado Tarella, Catherine Thieblemont, Thomas Tousseyn, Alessandra Tucci, Giorgio Vanini, Carlo Visco, Umberto Vitolo, Renata Walewska, Francesco Zaja, Thorsten Zenz, Pier Luigi Zinzani, Hossein Khiabanian, Arianna Calcinotto, Francesco Bertoni, Govind Bhagat, Elias Campo, Laurence De Leval, Stefan Dirnhofer, Stefano A. Pileri, Miguel A. Piris, Alexandra Traverse-Glehen, Alexander Tzankov, Marco Paulli, Maurilio Ponzoni, Luca Mazzucchelli, Franco Cavalli, Emanuele Zucca, Davide Rossi

Blood (2022) 139 (5): 732–747.

https://doi.org/10.1182/blood.2021012386

Published: 2022

Includes: Supplemental data

Journal Articles

Validation of New International Prognostic Scores, Including Baseline Peripheral Blood Variables, in Patients with Diffuse Large B-Cell Lymphoma and HIV Infection Treated with R-CHOP and Combined Antiretroviral Therapy. Retrospective Study from Spanish Lymphoma Group Geltamo

Blood (2021) 138 (Supplement 1): 2497.

https://doi.org/10.1182/blood-2021-148361

Published: 2021

Journal Articles

Rreal-World Results from Anti-CD19 CAR-T Cell Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Spain and Comparison with Previous Standard of Care: A Geltamo/Geth Study

Blood (2021) 138 (Supplement 1): 3850.

https://doi.org/10.1182/blood-2021-147670

Published: 2021

Journal Articles

Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study

Francesca Guidetti, Alessio Bruscaggin, PhD, Marco Frigeni, MD, Valeria Spina, PhD, Lodovico Terzi di Bergamo, Adalgisa Condoluci, MD, Gabriela Forestieri, Francesco Bertoni, MD, Luciano Cascione, PhD, Manuela Mollejo, Véronique Meignin, Alexandra Traverse-Glehen, MD PhD, Julia T Geyer, MD, Alessandro Broccoli, Alessandra Tucci, Silvia Bea, Renzo Boldorini, Gustavo Tapia, Antonino Maiorana, Maria Gomes da Silva, MD, Juan F. Garcia, Felicitas Hitz, Michele Merli, MD, Giorgio A. Vanini, Urban Novak, Francesco Piazza, Stefano Pizzolitto, Sascha Dietrich, Liliana Devizzi, Marco Ladetto, Maurilio Ponzoni, MD, Alessandro Rambaldi, MD, Paolo Corradini, Corrado Tarella, Elisa Santambrogio, Umberto Vitolo, Francesco Zaja, Francesco Passamonti, MD, Alexandar Tzankov, Sergio Cogliatti, Carlos Montalban, Roberto Marasca, MD, Laurence de Leval, MD, Carlo Visco, Maria Joao Baptista, PhD PharmD, Vincenzo Canzonieri, Estella Matutes, Fabio Facchetti, Marco Paulli, Elias Campo, David Oscier, Elena Sabattini, Pier Luigi Zinzani, MD, Govind Bhagat, Stefano A. Pileri, MD PhD, Giorgio Inghirami, MD, Gianluca Gaidano, MD PhD, Gilles Salles, MD PhD, Catherine Thieblemont, MD, Miguel A. Piris, Franco Cavalli, MD, Emanuele Zucca, Luca Arcaini, MD, Davide Rossi, MD PhD

Blood (2018) 132 (Supplement 1): 922.

https://doi.org/10.1182/blood-2018-99-115958

Published: 2018

Journal Articles

Efficacy of Autologous Stem Cell Transplantation in First Complete Remission in Patients with Peripheral T-Cell Lymphoma: A Multicenter Geltamo/FIL Study

Blood (2017) 130 (Supplement 1): 2008.

https://doi.org/10.1182/blood.V130.Suppl_1.2008.2008

Published: 2017

Journal Articles

Evaluation of the MD Anderson Tumor Score and Their Tumor Related Prognostic Variables in the Rituximab Era

Blood (2017) 130 (Supplement 1): 827.

https://doi.org/10.1182/blood.V130.Suppl_1.827.827

Published: 2017

Journal Articles

Geltamo-IPI Distinctly Identifies a Very High Risk Group in Difuse Large B-Cell Lymphoma (DLBCL) of Non B-Germinal-Center Origin Treated with Chemo-Immunotherapy

Blood (2017) 130 (Supplement 1): 1559.

https://doi.org/10.1182/blood.V130.Suppl_1.1559.1559

Published: 2017

Journal Articles

Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

Blood (2017) 130 (15): 1772–1774.

https://doi.org/10.1182/blood-2017-07-795302

Published: 2017

Journal Articles

Response-Adapted Treatment with Rituximab/Bendamustine/Mitoxantrone/Dexamethasone and Maintenance Therapy with Rituximab in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. RBMDGELTAMO08 Trial

Francisco Javier Peñalver Párraga, José Antonio Márquez Navarro, Soledad Durán Nieto, Pilar Giraldo Castellano, Carlos Montalbán Sanz, María José Ramírez Sánchez, Juan-Manuel Sancho Cia, María José Terol Castera, Francisco Javier Capote Huelva, Antonio Gutiérrez García, Blanca Sánchez González, Antonio Salar Silvestre, Miguel Canales Albendea, MD PhD, María Dolores Caballero Barrigón

Blood (2016) 128 (22): 1788.

https://doi.org/10.1182/blood.V128.22.1788.1788

Published: 2016

Journal Articles

Incidence, Risk Factors and Prognosis of Transformation in Follicular Lymphoma: a Multicentre Retrospective Analysis of 1763 Patients from the Geltamo Spanish Lymphoma Cooperative Group

Blood (2015) 126 (23): 3944.

https://doi.org/10.1182/blood.V126.23.3944.3944

Published: 2015

Journal Articles

Validation of the NCCN-IPI for Diffuse Large B-Cell Lymphoma (DLBCL) in a Nation-Wide Spanish Series of 1885 Patients. the Geltamo-IPI Project

Blood (2015) 126 (23): 3955.

https://doi.org/10.1182/blood.V126.23.3955.3955

Published: 2015

Journal Articles

Analysis of the Genomic Heterogeneity in Hodgkin Lymphoma Using Next Generation Sequencing

Elena Mata, Dr., Antonio Díaz-López, Dr., Ana M Martín-Moreno, Dr., Carlos Montalbán, MDPhD, Maria J Mestre, Dr., Carlos Santonja, Dr., Fernando Burgos, Dr., Javier Menárguez, Dr., Miguel A Piris, Dr., Juan F García, Dr.

Blood (2015) 126 (23): 178.

https://doi.org/10.1182/blood.V126.23.178.178

Published: 2015

Journal Articles

Screening Efectiveness with SERUM Galactomannan in High and Low Risk Patients for Fungal Infection in the Post ALLO-HTC

Fabio Augusto Ruiz Gómez, Jr., Valentin García Gutierrez, Sr., Elia Gomez, Sr., Pilar Herrera Puente, Sr., Isabel Page Herráez, Jr., Gustavo Alberto Pinto Solano, Jr., Carlos Montalban, Sr., PhD, Javier Lopez, Sr., MD PhD

Blood (2015) 126 (23): 5452.

https://doi.org/10.1182/blood.V126.23.5452.5452

Published: 2015

Journal Articles

Clinical Impact Of The Simultaneous Detection Of Anti-Erythocytic Autoantibodies In Alloimmunization

Maria C Tenorio Nuñez, PhD, Gemma Moreno Jimenez, MD, Manuel Hernandez Jodra, PhD, Lorena Abalo, MD, Juan Manuel Alonso, MD, Javier Garcia Lledo, MD, Jose Valentin Garcia Gutierrez, PhD, Carlos Montalban, PhD, Concepcion Zamora De Pedro, PhD, Francisco Javier Lopez Jimenez, PhD

Blood (2013) 122 (21): 4828.

https://doi.org/10.1182/blood.V122.21.4828.4828

Published: 2013

Journal Articles

A Randomized Phase II Study Comparing Consolidation With a Single Dose Of 90 y Ibritumomab Tiuxetan (Zevalin®) (Z) Vs. Maintenance With Rituximab (R) For Two Years In Patients With Newly Diagnosed Follicular Lymphoma (FL) Responding To R-CHOP. Preliminary Results At 36 Months From Randomization

Blood (2013) 122 (21): 369.

https://doi.org/10.1182/blood.V122.21.369.369

Published: 2013

Journal Articles

Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. R-BMD Geltamo 08 Trial

Francisco Javier Peñalver, José Antonio Márquez, Soledad Durán, Pilar Giraldo, Carlos Montalban, María José Ramírez, Juan Manuel Sancho, María José Terol, MD, PhD, Francisco Javier Capote, Antonio Gutiérrez, Blanca Sánchez, Miguel Canales, María Dolores Caballero

Blood (2012) 120 (21): 1639.

https://doi.org/10.1182/blood.V120.21.1639.1639

Published: 2012

Journal Articles

The Pretreatment Absolute Lymphocyte Count (ALC), but Not the Absolute Monocyte Count (AMC) or ALC/AMC Ratio, Is an Independent Prognostic Factor in Aggressive Non-Hodgkin Lymphoma (aNHL)

Noridza Rivera-Rodriguez, MD, Fernando Cabanillas, MD, Carlos Montalban, Jose Francisco Tomas, MD, María José Terol, MD, PhD, Armando López-Guillermo, MD, Wandaly I. Pardo, MD, Orestes A. Pavia, MD, Margarita Bruno, MD, Karen Janice Santiago, Pablo Guisado-Vasco, MD, PhD, Angel Ruedas, MD, Raquel de Oña, Silvia Solorzano, Ana Isabel Teruel, MD, Laura Garcia-Sanchis, Jordina Rovira, MD, Ivan Dlouhy

Blood (2012) 120 (21): 1596.

https://doi.org/10.1182/blood.V120.21.1596.1596

Published: 2012

Journal Articles

Personalized Treatment with low doses of Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma in frail or Elderly Patients

Angel Ruedas, MD, Pablo Guisado, MD, PhD, Beatriz Aguado, MD, PhD, Ricardo Perez, MD, Joaquin Martinez, MD, J Valentin Garcia-Gutierrez, MD, PhD, M. Jesús Blanchard, MD, Pilar Bravo, MD, Carlos Montalban

Blood (2012) 120 (21): 5049.

https://doi.org/10.1182/blood.V120.21.5049.5049

Published: 2012

Journal Articles

Final Results of a Multicenter Phase II Trial with Bendamustine and Rituximab As First Line Treatment for Patients with MALT Lymphoma (MALT-2008–01)

Antonio Salar, MD, Eva Domingo-Domenech, MD, Carlos Panizo, Concepción Nicolás, MD, Joan Bargay, Ana Muntanola, MD, Miguel Canales, Jose Luis Bello, MD, juan Manuel Sancho, Sr., MD, Jose Francisco Tomas, MD, María José Rodriguez, MD, Francisco-Javier Penalver, Luis Palomera, MD, Carlos Grande, José J Sánchez-Blanco, MD, Reyes Arranz, MD, Eulogio Conde, Dolores Caballero, MD, Carlos Montalban

Blood (2012) 120 (21): 3691.

https://doi.org/10.1182/blood.V120.21.3691.3691

Published: 2012

NARROW

Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group

Genetic and phenotypic attributes of splenic marginal zone lymphoma

Validation of New International Prognostic Scores, Including Baseline Peripheral Blood Variables, in Patients with Diffuse Large B-Cell Lymphoma and HIV Infection Treated with R-CHOP and Combined Antiretroviral Therapy. Retrospective Study from Spanish Lymphoma Group Geltamo

Rreal-World Results from Anti-CD19 CAR-T Cell Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Spain and Comparison with Previous Standard of Care: A Geltamo/Geth Study

Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study

Efficacy of Autologous Stem Cell Transplantation in First Complete Remission in Patients with Peripheral T-Cell Lymphoma: A Multicenter Geltamo/FIL Study

Evaluation of the MD Anderson Tumor Score and Their Tumor Related Prognostic Variables in the Rituximab Era

Geltamo-IPI Distinctly Identifies a Very High Risk Group in Difuse Large B-Cell Lymphoma (DLBCL) of Non B-Germinal-Center Origin Treated with Chemo-Immunotherapy

Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

Response-Adapted Treatment with Rituximab/Bendamustine/Mitoxantrone/Dexamethasone and Maintenance Therapy with Rituximab in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. RBMDGELTAMO08 Trial

Incidence, Risk Factors and Prognosis of Transformation in Follicular Lymphoma: a Multicentre Retrospective Analysis of 1763 Patients from the Geltamo Spanish Lymphoma Cooperative Group

Validation of the NCCN-IPI for Diffuse Large B-Cell Lymphoma (DLBCL) in a Nation-Wide Spanish Series of 1885 Patients. the Geltamo-IPI Project

Analysis of the Genomic Heterogeneity in Hodgkin Lymphoma Using Next Generation Sequencing

Screening Efectiveness with SERUM Galactomannan in High and Low Risk Patients for Fungal Infection in the Post ALLO-HTC

Clinical Impact Of The Simultaneous Detection Of Anti-Erythocytic Autoantibodies In Alloimmunization

A Randomized Phase II Study Comparing Consolidation With a Single Dose Of 90 y Ibritumomab Tiuxetan (Zevalin®) (Z) Vs. Maintenance With Rituximab (R) For Two Years In Patients With Newly Diagnosed Follicular Lymphoma (FL) Responding To R-CHOP. Preliminary Results At 36 Months From Randomization

Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. R-BMD Geltamo 08 Trial

The Pretreatment Absolute Lymphocyte Count (ALC), but Not the Absolute Monocyte Count (AMC) or ALC/AMC Ratio, Is an Independent Prognostic Factor in Aggressive Non-Hodgkin Lymphoma (aNHL)

Personalized Treatment with low doses of Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma in frail or Elderly Patients

Final Results of a Multicenter Phase II Trial with Bendamustine and Rituximab As First Line Treatment for Patients with MALT Lymphoma (MALT-2008–01)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only